Trialbee Taps Veteran Exec Rick Riegel to Steer Global Expansion

MALMO, Sweden & WILMINGTON, Del. – March 10, 2026 – Trialbee, a leader in technology-driven patient recruitment, has appointed life sciences veteran Rick Riegel to its Board of Directors in a strategic move designed to accelerate its global growth. The appointment comes on the heels of a majority investment from Varsity Healthcare Partners (VHP) and signals a concerted effort by the company to solidify its leadership in a market rapidly being reshaped by artificial intelligence and data analytics.

Riegel’s addition to the board is a clear indicator of Trialbee’s ambitions. With a career spanning over three decades, he brings a formidable track record of scaling high-growth technology companies within the life sciences sector, an experience set that aligns directly with Trialbee’s current trajectory.

A Strategic Play for Global Leadership

Rick Riegel is widely recognized for his ability to steer companies through critical growth phases toward successful financial outcomes. As CEO of LIQUENT, he orchestrated its sale to the clinical research giant PAREXEL. Later, as CEO of Phlexglobal, a provider of Trial Master File (TMF) solutions, he led the company through a period of significant growth and a successful private equity exit. His current role leading LMC Advisory, LLC, and his numerous board positions—including Chairman at Deerfield Group and Director at RealTime eClinical Solutions—place him at the nexus of investment and innovation in life sciences.

This expertise is precisely what Trialbee sought as it embarks on its next chapter, fueled by the recent investment from VHP. The private equity firm, known for its "buy and build" strategy, aims to enhance operational capabilities and drive aggressive growth in its portfolio companies. Riegel's appointment is a key part of that playbook, adding a layer of seasoned strategic oversight to the company’s expansion plans.

“Rick has consistently demonstrated an ability to scale organizations, sharpen strategic focus, and deliver measurable impact for customers—expertise that will be critical as Trialbee furthers our mission of redefining Global Patient Recruitment and improving enrollment outcomes,” said Matt Walz, CEO of Trialbee. Walz also noted Riegel’s long-standing role as a mentor and advisory board member, highlighting a pre-existing trust and strategic alignment.

Reshaping Recruitment with AI and Data

The appointment comes at a time when the clinical trial industry is grappling with persistent inefficiencies. Over 80% of trials fail to meet their recruitment timelines, a bottleneck that delays the development of new therapies and inflates costs. In response, the patient recruitment services market is projected to swell from approximately $1.11 billion in 2023 to over $1.66 billion by 2031, with much of that growth driven by the adoption of digital and AI-powered solutions.

Trialbee has positioned itself at the forefront of this technological shift with its Honey Platform™. The platform integrates patient outreach, medical pre-qualification, and analytics into a single system powered by embedded AI. This data-driven approach moves beyond traditional methods, using predictive analytics and machine learning to sift through vast datasets—including electronic health records and real-world data—to identify and engage suitable candidates with greater precision.

The company’s technology supports a vast operational footprint, having managed over 1.6 million patient journeys across 6,000 research sites in 50 countries. This global reach is critical for sponsors like Eli Lilly, Bristol Myers Squibb, and Sanofi, who rely on Trialbee to recruit diverse patient populations for complex international studies.

“The company’s data-driven approach, embedded AI capabilities, and expanding global footprint are delivering measurable impact across the industry and setting a new standard for performance,” Riegel stated. “The recent investment from Varsity Healthcare Partners reflects the strength of that progress and positions Trialbee to scale its platform and partnerships even further.”

Driving Efficiency and Expanding Access

The tangible results of Trialbee's model are reflected in its key performance metrics. The company reports a 91% repeat business rate, a figure that suggests a high degree of client satisfaction and trust among leading biopharmaceutical companies and contract research organizations (CROs). This loyalty is built on delivering predictable and efficient enrollment.

Perhaps more telling is its reported 30% referral-to-consent ratio, a metric indicating the percentage of pre-qualified patients who are ultimately enrolled in a trial. This figure is reportedly double the industry average, showcasing the platform's effectiveness in eliminating unqualified candidates early in the process. Such efficiency is invaluable to research sites, reducing their screening burden and allowing them to focus on eligible, engaged participants.

By optimizing the "last mile" of patient recruitment, Trialbee not only accelerates trial timelines but also broadens the potential for more equitable access to clinical research. As regulatory bodies increasingly mandate diversity in trial populations, the ability to precisely target and engage underrepresented groups becomes a competitive and ethical imperative. The company's technology, combined with its global partner network, helps democratize access, ensuring that medical advancements are tested on populations that reflect the real world.

With Riegel’s strategic guidance now formally integrated at the board level and backed by significant new capital, Trialbee is poised to deepen its enterprise partnerships and enhance its technological capabilities. The move solidifies its strategy to not just participate in the evolution of clinical trial recruitment but to actively lead it, setting new benchmarks for speed, efficiency, and patient-centricity on a global scale.